Study S000540

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07467447
Acronym: GZBF
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: RECRUITING
Enrollment: 300
Start: 2026-02-15
Primary completion: 2027-03-14
Lead sponsor: Hudson Biotech
Conditions: Obesity
Interventions: DRUG:Retatrutide (LY3437943); DRUG:Placebo; BEHAVIORAL:Standardized diet and physical activity counseling throughout the study.
Results posted: FALSE

Registered primary outcomes

Mean percent change in body weight from randomization/baseline to Week 24. [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.